Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAITH study of 5 versus 3 years of adjuvant imatinib after resection of high-risk GIST
ChiCTR1800015245Phase 4Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Relapse-free survival. Started Apr 2018; status: recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR1800015245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015245.